GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk

Background GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients with chronic inflammatory and autoimmune diseases. GlycA is unique in its composite nature, reflecting both increased glycan comp...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of translational medicine Ročník 15; číslo 1; s. 219 - 5
Hlavní autori: Connelly, Margery A., Otvos, James D., Shalaurova, Irina, Playford, Martin P., Mehta, Nehal N.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London BioMed Central 27.10.2017
BioMed Central Ltd
Springer Nature B.V
BMC
Predmet:
Acetylglucosamine - blood
Biological markers
Biomarkers - blood
Biomedical and Life Sciences
Biomedicine
C-Reactive Protein - metabolism
Cardiovascular
Cardiovascular disease
Cardiovascular diseases
Cardiovascular Diseases - blood
Cardiovascular Diseases - mortality
GlycA
Health aspects
Health risk assessment
Humans
Identification and classification
Inflammation
Inflammation - blood
Medicine/Public Health
Metabolic and Lipoprotein Translation
Mortality
NMR
Nuclear magnetic resonance
Nuclear magnetic resonance spectroscopy
Review
Risk Factors
Nuclear magnetic resonance spectroscopy
GlycA
Cardiovascular disease
Inflammation
ISSN:1479-5876, 1479-5876
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Background GlycA is a novel spectroscopic marker of systemic inflammation with low intra-individual variability and other attributes favoring its clinical use in patients with chronic inflammatory and autoimmune diseases. GlycA is unique in its composite nature, reflecting both increased glycan complexity and circulating acute phase protein levels during local and systemic inflammation. Recent studies of GlycA from cross-sectional, observational and interventional studies have been highly informative, demonstrating that GlycA is elevated in acute and chronic inflammation, predicts death in healthy individuals and is associated with disease severity in patients with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis and lupus. Moreover, following treatment with biological therapy in psoriasis, reduction in skin disease severity was accompanied by a decrease in GlycA levels and improvement in vascular inflammation. Conclusions Collectively, these findings suggest GlycA is a marker that tracks systemic inflammation and subclinical vascular inflammation. However, larger prospective studies and randomized trials are necessary in order to assess the impact of novel therapies on GlycA in patients with chronic inflammatory conditions, which may be concomitant with cardiovascular benefits.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1479-5876
1479-5876
DOI:10.1186/s12967-017-1321-6